Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru® with the US Food and Drug Administration (FDA)

1 Oct 2018

Shield Therapeutics plc, today announces that it has received confirmation from the US FDA of its successful submission of an NDA for Feraccru®. For more details please see the press release below.

STX_NDA submission

Back to news